Who we are

CIS region has undergoing major changes in regulatory framework related to Eurasian Economic Union (EAEU) regulations. PharmaLex is a global company with local representatives operating all over the globe region, including CIS. We have established and maintained a global network of local representatives in the CIS region since 2012.

  • Countries: Russia, Kazakhstan, Uzbekistan, Tajikistan, Kyrgistan, Mongolia, Turkmenistan, Ukraine, Belarus, Georgia, Azerbaijan, Armenia and Moldova.
  • Well-established local representatives with local expertise and connections.
  • Established access and f2F meetings with the Health Authorities, such as FGBU (Russia).
  • We cover all of the services offered by PharmaLex across the CIS region, including end-to-end services from the pre-submission regulatory strategy, to the marketing authorisation and the life cycle management activities.

For customers looking for support in the CIS region, PharmaLex offers the option to have a single point of contact, who will manage and oversee entire functions as well as manage the liaison between our customers and our local experts on site.

Local Contact

  • Laura Monkiene
    Director, Principal Consultant Regulatory Affairs
Download Terms and Conditions

What our clients say about us

We are working with a number of large pharma companies and are looking to create a consortium of partners to collect feedback on expertise, availability and outcomes. If you would be interested in joining our consortium, please contact us on contact@pharmalex.com.

  • In these unprecedented times, PharmaLex continues to support all clients by meeting virtually and providing experienced, remote-based consultants.

    Thomas Dobmeyer, CEO PharmaLex
    CEO PharmaLex

  • We needed a partner to help us obtain device approval. PharmaLex have not only helped us achieve this but are now providing on-going post-marketing surveillance support. We would highly recommend them to anyone who needs specialist expertise.

    Med Device company, US
    Senior Regulatory Affairs Director

  • There was a close relationship between the regulatory strategy and the writing activities. You developed a fine-tuned regulatory strategy which will be a key factor to smooth the approval of our dossier.

    Large Pharma, Global
    VP Regulatory Strategy

  • We needed to develop our strategy and PharmaLex had exactly the experience we needed.

    Med Device company, UK
    Senior QA Director

Related News